Advertisement

Desmoid Tumours in Familial Adenomatous Polyposis

  • Francesco Tonelli
  • Lucia Picariello
  • Gabriella Nesi
  • Alessandro Franchi
  • Rosa Valanzano
  • Corrado R. Asteria
  • Maria Luisa Brandi

Keywords

Familial Adenomatous Polyposis Desmoid Tumor Sulindac Sulfide Mesenteric Fibromatosis Sulindac Sulphide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Muller J (1838) Ueber den feinern Bau und die Formen der krankhaften Geschwulste. Reimer, BerlinGoogle Scholar
  2. 2.
    Gurbuz AK, Giardiello FM, Petersen GM et al (1994) Desmoid tumors in familial adenomatous polyposis. Gut 35:377–381PubMedGoogle Scholar
  3. 3.
    Tonelli F (1978) Abdominal desmoids and mesenteric fibromatosis in familial polyposis of the colon. Ital J Gastroenterol 10:27–36Google Scholar
  4. 4.
    Simpson RD, Harrison EG, Mayo CW (1964) Mesenteric fibromatosis in familial polyposis: a variant of Gardner’s syndrome. Cancer 17:526–534PubMedCrossRefGoogle Scholar
  5. 5.
    Richards RC, Rogers SW, Gardner EJ (1981) Spontaneous mesenteric fibromatosis in Gardner’s syndrome. Cancer 47: 597–601PubMedCrossRefGoogle Scholar
  6. 6.
    Clark SK, Johnson Smith TGP, Katz DE et al (1998) Identification and progression of a desmoid precursor lesion in patients with familial adenomatous polyposis. Br J Surg 85:970–975PubMedCrossRefGoogle Scholar
  7. 7.
    Middleton SB, Clark SK, Matravers P et al (2003) Stepwise progression of familial adenomatous polyposisassociated desmoid precursor lesions demonstrated by a novel CT scoring system Dis Colon Rectum 46:481–485PubMedCrossRefGoogle Scholar
  8. 8.
    Healey JC, Reznek RH, Clark SK et al (1997) MR appearances of desmoid tumours in familial adenomatous polyposis. Am J Roentgenol 169:465–472Google Scholar
  9. 9.
    Brooks AP, Reznek RH, Nugent K et al (1994) CT appearances of desmoid tumors in familial adenomatous polyposis: further observations. Clin Radiol 49:601–607PubMedCrossRefGoogle Scholar
  10. 10.
    Knudsen AL, Bulow S (2001) Desmoid tumour in familial adenomatous polyposis: a review of literature. Famil Cancer 1:111–119Google Scholar
  11. 11.
    Jarvinen HJ (1997) Desmoid disease as a part of familial adenomatous polyposis coli. Acta Chir Scand 153:379–383Google Scholar
  12. 12.
    Bertario L, Russo A, Sala P et al (2001) Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 95:102–107PubMedCrossRefGoogle Scholar
  13. 13.
    Penna C, Tiret E, Parc R et al (1993) Operation and abdominal desmoid tumors in familial adenomatous polyposis. Surg Gynecol Obstet 177:263–268PubMedGoogle Scholar
  14. 14.
    Jones IT, Fazio VW, Weakley FL et al (1986) Desmoid tumors in familial polyposis coli. Ann Surg 204:94–97 Lofti AM, Dozois RR, Gordon H et al (1989) Mesenteric fibromatosis complicating familial adenomatous polyposis: predisposing factors and results of treatment. Int J Colorectal Dis 4:30–36PubMedCrossRefGoogle Scholar
  15. 15.
    Lofti AM, Dozois RR, Gordon H et al (1989) Mesenteric fibromatosis complicating familial adenomatous polyposis: predisposing factors and results of treatment. Int J Colorectal Dis 4:30–36CrossRefGoogle Scholar
  16. 16.
    Rodriguez-Bigas MA, Mahoney MC, Karakousis CP et al (1994) Desmoid tumors in patients with familial adenomatous polyposis. Cancer 74:1270–1274PubMedCrossRefGoogle Scholar
  17. 17.
    Kadmon M, Möslein G, Buhr H et al (1995) Desmoide bei Patienten mit familiärer adenomatöser Polyposis (FAP). Chirurg 66:997–1005PubMedGoogle Scholar
  18. 18.
    Heiskanen I, Jarvinen HJ (1997) Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Int J Colorectal Dis 11:157–162CrossRefGoogle Scholar
  19. 19.
    Soravia C, Berk T, McLeod RS et al (2000) Desmoid disease in patients with familial adenomatous polyposis. Dis Colon Rectum 43:363–369PubMedCrossRefGoogle Scholar
  20. 20.
    Ho JW, Chu KM, Tse CW, Yuen ST (2002) Phenotype and management of patients with familial adenomatous polyposis in Hong Kong: perspective of the Hereditary Gastrointestinal Cancer Registry. Hong Kong Med J 2002 Oct;8(5):342–347PubMedGoogle Scholar
  21. 21.
    Church JM (1998) Mucosal ischaemia caused by desmoid tumors in patients with familial adenomatous polyposis. Dis Colon Rectum 41: 661–663PubMedCrossRefGoogle Scholar
  22. 22.
    Tulchinsky H, Keidar A, Strul H et al (2005) Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy Arch Surg 140:159–163PubMedCrossRefGoogle Scholar
  23. 23.
    Arvanitis ML, Jagelman DG, Fazio VW et al (1990) Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 33:639–642PubMedCrossRefGoogle Scholar
  24. 24.
    Iwama T, Myshima Y, Utsunomiya J (1993) The impact of familial adenomatous polyposis on the tumorigenesis and mortality at several organs: its rational treatment. Ann Surg 217:99–100CrossRefGoogle Scholar
  25. 25.
    Bertario L, Presciuttini S, Sala P et al (1994) Causes of death and post-surgical survival in familial adenomatous polyposis: results from the Italian Registry of Familial Adenomatous Polyposis Writing Committee. Semin Surg Oncol 10:225–234PubMedCrossRefGoogle Scholar
  26. 26.
    Sagar PM, Moslein G, Dozois RR (1998) Management of desmoid tumors in patients after ileal pouch-anal anastomosis for familial adenomatous polyposis. Dis Colon Rectum 41:1350–1356PubMedCrossRefGoogle Scholar
  27. 27.
    Parc Y, Piquard A, Dozois RR et al (2004) Long-term outcome of familial adenomatous polyposis patients after restorative coloproctectomy. Ann Surg 239:378–382PubMedCrossRefGoogle Scholar
  28. 28.
    Middleton SB, Frayling IF, Phillips RK (2000) Desmoids in familial adenomatous polyposis are monoclonal proliferations. Br J Cancer 82:828–832CrossRefGoogle Scholar
  29. 29.
    Li C, Bapat B, Alman BA (1998) Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin regulatory function in aggressive fibromatosis (desmoid tumors). Am J Pathol 153:709–714PubMedGoogle Scholar
  30. 30.
    McAdam WA, Goligher IC (1970) The occurrence of desmoids in patients with familial polyposis coli. Br J Surg 57:618–631PubMedGoogle Scholar
  31. 31.
    Clark SK, Neale KF, Landgrebe JC et al (1999) Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 86:1185–1189PubMedCrossRefGoogle Scholar
  32. 32.
    Sturt NJH, Gallagher MC, Bassett P et al (2004) Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 53:1832–1836PubMedCrossRefGoogle Scholar
  33. 33.
    Caldwell EH (1976) Desmoid tumor: musculoaponeurotic fibrosis of the abdominal wall. Surgery 79:104–106PubMedGoogle Scholar
  34. 34.
    Eagel BA, Zentler-Munro P, Smith IE (1989) Mesenteric tumours in Gardner’s syndrome: review of medical treatment. Postgrd Med J 65:497–501Google Scholar
  35. 35.
    Church JM, McGannon E (2000) Prior pregnancy ameliorates the course of intra-abdominal desmoid tumors in patients with familial adenomatous polyposis. Dis Colon Rectum 43:445–450PubMedCrossRefGoogle Scholar
  36. 36.
    Miyaki M, Konishi M, Kikuchi-Yanoshita R et al (1993) Coexistence of somatic and germ-line mutations of APC gene in desmoid tumors from patients with familial adenomatous polyposis. Cancer Res 53:5079–5082PubMedGoogle Scholar
  37. 37.
    Palmirotta R, Curia MC, Esposito DL et al (1995) Novel mutations and inactivations of both alleles of the AP gene in desmoid tumors. Hum Mol Genet 4:1979–1981PubMedCrossRefGoogle Scholar
  38. 38.
    Caspari R, Olschwang S, Friedl W et al (1995) Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 4:337–340PubMedCrossRefGoogle Scholar
  39. 39.
    Couture J, Mitri A, Lagace R et al (2000) A germline mutation at the extreme 3’ end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumour. Clin Genet 57:205–212PubMedCrossRefGoogle Scholar
  40. 40.
    Eccles DM, van der Lujit R, Breukel C (1996) Hereditary desmoid disease due to a frameshift mutation at codon 1924 of the gena APC. Am J Hum Mut 59:1193–1201Google Scholar
  41. 41.
    Tonelli F, Valanzano R, Brandi ML (1994) Pharmacologic treatment of desmoid tumors in familial adenomatous polyposis: results of an in vitro study. Surgery 115:473–479PubMedGoogle Scholar
  42. 42.
    Picariello L, Fiorelli G, Benvenuti S et al (1997) In vitro bioeffects of the antiestrogen LY117018 on desmoid tumor and colon cancer cells. Anticancer Res 17:2099–2104PubMedGoogle Scholar
  43. 43.
    Locci P, Bellocchio S, Lilli C et al (2001) Synthesis and secretion of transforming growth factor-ß1 by human desmoid fibroblast cell line and its modulation by toremifene. J Interferon and Cytokine Res 21:961–970CrossRefGoogle Scholar
  44. 44.
    Waddell WR, Gerner RE, Reich MP (1983) Non steroidal anti-inflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J Surg Oncol 22:197–211PubMedCrossRefGoogle Scholar
  45. 45.
    Kedar RP, Bourne TH, Powles TJ et al (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343:1318–1321PubMedCrossRefGoogle Scholar
  46. 46.
    Fisher B, Costantino JP, Redmand CK et al (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537PubMedCrossRefGoogle Scholar
  47. 47.
    Clark SK, Phillips RKS (1996) Desmoids in familial adenomatous polyposis. Br J Surg 83:1494–1504PubMedGoogle Scholar
  48. 48.
    Brooks MD, Ebbs SR, Colletta AA et al (1992) Desmoid tumors treated with triphenylethylenes. Eur J Cancer 28:1014–1018CrossRefGoogle Scholar
  49. 49.
    Hansmann A., Adolph C, Vogel T et al (2003) Highdose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100:612–620CrossRefGoogle Scholar
  50. 50.
    Tonelli F, Ficari F, Valanzano R et al (2003) Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori 89:391–396PubMedGoogle Scholar
  51. 51.
    Taketo M (1998) Cyclooxigenase-2 inhibitors in tumorogenesis (part I). J Natl Cancer Inst 90:1529–1536PubMedCrossRefGoogle Scholar
  52. 52.
    Taketo M (1998) Cyclooxigenase-2 inhibitors in tumorogenesis (part II). J Natl Cancer Inst 90:1609–1620PubMedCrossRefGoogle Scholar
  53. 53.
    Janne PA, Mayer RJ (2000) Chemoprevention of colorectal cancer. N Engl J Med 342:1960–1968PubMedCrossRefGoogle Scholar
  54. 54.
    Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231:232–235Google Scholar
  55. 55.
    Du Bois RN, Abramson SB, Crofford L et al (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063–1073Google Scholar
  56. 56.
    Smith WL, Garavito RM, DeWitt (1996) Prostaglandin endo-peroxide H synthases (Cyclooxygenase)-1 and-2. J Biol Chem 271:33157–33160PubMedCrossRefGoogle Scholar
  57. 57.
    Xie W, Robertson D, Simmons D (1992) Mitogeninducible prostaglandin G/H synthase: a new target for nonsteroidal anti-inflammatory drugs. Drug Dev Res 25:249–265CrossRefGoogle Scholar
  58. 58.
    Morrow JD, Roberts LJ (2001) Lipid-derived autacoids. In: Hardman JG, Limbird LE (eds) The pharmacological basis of therapeutics. McGraw-Hill, New York, pp 669–685Google Scholar
  59. 59.
    Roberts LJ, Morrow JD (2001) Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE (eds) The pharmacological basis of therapeutics. McGraw-Hill, New York, pp 687–731Google Scholar
  60. 60.
    Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-doses aspirin in healthy subjects. J Clin Invest 69:1366–1372PubMedGoogle Scholar
  61. 61.
    FitzGerald GA, Oates JA, Hawiger J et al (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71:678–688Google Scholar
  62. 62.
    Roth GJ, Majerus P (1975) The mechanism of the effect of aspirin on human platelets: acetylation of a particulate protein fraction. J Clin Invest 56:624–632PubMedCrossRefGoogle Scholar
  63. 63.
    Lecomte M, Laneuville O, Ji C et al (1994) Acetylation of human prostaglandin endo-peroxide synthase-2(cyclooxygenase-2) by aspirin. J Biol Chem 269:13207–13215PubMedGoogle Scholar
  64. 64.
    Cipollone F, Patrignani P, Greco A et al (1997) Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulatio 96:1109–1116Google Scholar
  65. 65.
    Vane JR (1994) Towards a better aspirin. Nature 367:215–216PubMedCrossRefGoogle Scholar
  66. 66.
    Stolina M, Sharma S, Zhu L et al (2000) Lung cancer cyclooxygenase-2 dependent inhibition of dendritic cell maturation and function. Pro Am Assoc Cancer Res 41:619 (abstract 620)Google Scholar
  67. 67.
    Tsujii M, DuBois RN (1995) Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endo-peroxide synthase 2. Cell 83:493–501PubMedCrossRefGoogle Scholar
  68. 68.
    He TC, Chan TA, Vogelstein B et al (1999) PPAR-delta is an APC-regulated target of nonsteroidal antiinflammatory drugs. Cell 99:335–345PubMedCrossRefGoogle Scholar
  69. 69.
    Afford S, Randhawa S (2000) Apoptosis. Mol Pathol 53:55–63PubMedCrossRefGoogle Scholar
  70. 70.
    Bedi A, Pasricha PJ, Akhtar AJ et al (1995) Inhibition of apoptosis during development of colorectal cancer. Cancer Res 55:1811–1816PubMedGoogle Scholar
  71. 71.
    Pasricha PJ, Bedi A, O’Connor K et al (1995) The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 109:994–998PubMedCrossRefGoogle Scholar
  72. 72.
    Uefuji K, Ichikura T, Shinomiya N et al (2000) Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor in human gastric cancer cell lines. Anticancer Res 20:4279–4284PubMedGoogle Scholar
  73. 73.
    Souza RF, Shewmake K, Beer DG et al (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human oesophageal adenocarcinoma cells. Cancer Res 60:5767–5772PubMedGoogle Scholar
  74. 74.
    Sumitani K, Kamijo R, Toyoshima T et al (2001) Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med 30:41–47PubMedCrossRefGoogle Scholar
  75. 75.
    Joki T, Heese O, Nikas DC et al (2000) Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 60:4926–4931PubMedGoogle Scholar
  76. 76.
    Tsubouchi Y, Mukai S, Kawaito Y et al (2000) Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 20:2867–2872PubMedGoogle Scholar
  77. 77.
    Molina MA, Sitja-Arnau M, Lemoine MG et al (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59:4356–4362PubMedGoogle Scholar
  78. 78.
    Marx J (2001) Cancer research. Anti-inflammatories inhibit cancer growth, but how? Science 291:581–582PubMedCrossRefGoogle Scholar
  79. 79.
    Scorrano L, Penzo D, Petronilli V et al (2001) Arachidonic acid causes cell death through the mitochondrial permeability transition: implications for tumor necrosis factor-alpha apoptotic signalling. J Biol Chem 276:12035–12040PubMedCrossRefGoogle Scholar
  80. 80.
    Grosch S, Tegeder I, Niederberg E et al (2001) COX-2 independent induction of cell arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15:2742–2744PubMedGoogle Scholar
  81. 81.
    Shureiqi I, Chen D, Lotan R et al (2000) 15-lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 60:6846–6850PubMedGoogle Scholar
  82. 82.
    Leahy KM, Ornberg RL, Wang et al. (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:625–631PubMedGoogle Scholar
  83. 83.
    Tsujii M, Kawano S, Tsujii S et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716PubMedCrossRefGoogle Scholar
  84. 84.
    Dannenberg AJ, Altorki NK, Boyle JO et al (2001) Cyclo-oxygenase 2: a pharmacological target for prevention of cancer. Lancet Oncol 2:544–551PubMedCrossRefGoogle Scholar
  85. 85.
    Araki Y, Okamura S, Hussain S et al (2003) Regulation of cyclooxygenase-2 expression by the Wnt and Ras pathways. Cancer Res 63:728–734PubMedGoogle Scholar
  86. 86.
    Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and anti-tumour activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306–1311PubMedGoogle Scholar
  87. 87.
    Jones MK, Wang H, Peskar BM et al (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5:1418–1423PubMedCrossRefGoogle Scholar
  88. 88.
    Brueggemeier RW, Quinn AL, Parrett ML et al (1999) Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140:27–35PubMedCrossRefGoogle Scholar
  89. 89.
    Tejpar S, Nollet F, Li C et al (1999) Predominance of-catenin mutations and-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 18:6615–6620PubMedCrossRefGoogle Scholar
  90. 90.
    Sparks AB, Morin PJ, Vogelstain B et al (1998) Mutational analysis of the APC/-catenin/Tcf pathway in colorectal cancer. Cancer Res 58:1130–1134PubMedGoogle Scholar
  91. 91.
    Williams CS, Smalley W, DuBois RN (1997) Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 100:1325–1359PubMedGoogle Scholar
  92. 92.
    Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908–7916PubMedCrossRefGoogle Scholar
  93. 93.
    Oshima M, Dinchuk JE, Kargman SL et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803–809PubMedCrossRefGoogle Scholar
  94. 94.
    Picariello L, Brandi ML, Formigli L et al (1998) Apoptosis induced by sulindac sulfide in epithelial and mesenchymal cells from human abdominal neoplasms. Eur J Pharm 360:105–112CrossRefGoogle Scholar
  95. 95.
    Poon R, Smits R, Catherine L et al (2001) Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 20:451–460PubMedCrossRefGoogle Scholar
  96. 96.
    Tsukada K, Church JM, Jagelman DG et al (1992) Noncytotoxic drug therapy for intra-abdominal desmoid tumors in patients with familial adenomatous polyposis. Dis Colon Rectum 35:29–33PubMedCrossRefGoogle Scholar
  97. 97.
    Klein WA, Miller HH, Anderson M et al (1987) The use of indomethacin, sulindac and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 60:2863–2868PubMedCrossRefGoogle Scholar
  98. 98.
    Waddell WR, Kirsch WM (1991) Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg 161:416–421PubMedCrossRefGoogle Scholar
  99. 99.
    Geurs F, Kok TC (1993) Regression of a great abdominal desmoid tumor by interferon-alpha. J Clin Gastrenterol 16:264–265CrossRefGoogle Scholar
  100. 100.
    Heidemann J, Ogawa H, Otterson MF et al (2004) Antiangiogenic treatment of mesenteric desmoid tumors with toremifene and interferon alfa-2b: report of two cases. Dis Colon Rectum 47:118–122PubMedCrossRefGoogle Scholar
  101. 101.
    Nakada J, Ubukata H, Goto Y et al (1997) Prednisolone therapy for intra-abdominal desmoid tumours in a patient with familial adenomatous polyposis. Gastroenterol 32:255–259CrossRefGoogle Scholar
  102. 102.
    Lindor NM, Dozois RR, Nelson H et al (2003) Desmoid tumors in familial adenomatous polyposis: a pilot project evaluating efficacy of treatment with pirfenidone. Am J Gastroenterol 98:1868–1874PubMedCrossRefGoogle Scholar
  103. 103.
    Mace J, Biermann JS, Sondak V et al (2002) Response of extra-abdominal desmoid tumors to therapy with imatinib mesylate. Cancer 95:237–239CrossRefGoogle Scholar
  104. 104.
    Tsukada K, Church JM, Jagelman DG et al (1991) Systemic cytotoxic chemotherapy and radiation therapy for desmoid in familial adenomatous polyposis. Dis Colon Rectum 34:1090–1092PubMedCrossRefGoogle Scholar
  105. 105.
    Patel SR, Evans HL, Benjamin RS (1992) Combination chemotherapy in adult desmoid tumors. Cancer 72:3244–3247CrossRefGoogle Scholar
  106. 106.
    Lynch HT, Fitzgibbons R Jr, Chong S et al (1994) Use of doxorubicin and dacarbazine for the management of unresectable intraabdominal desmoid tumors in Gardner’s syndrome. Dis Colon Rectum 37:260–267PubMedCrossRefGoogle Scholar
  107. 107.
    Schnitzler M, Cohen Z, Blackstein M et al (1997) Chemotherapy for desmoid tumors in association with familial adenomatous polyposis. Dis Colon Rectum 40:798–801PubMedCrossRefGoogle Scholar
  108. 108.
    Risum S, Bulow S (2003) Doxorubicin treatment of an intra-abdominal desmoid tumour in a patient with familial adenomatous polyposis. Colorectal Dis 5:585–586PubMedCrossRefGoogle Scholar
  109. 109.
    Okuno SH, Edmonson JH (2003) Combination chemotherapy for desmoid tumors. Cancer 97:1134–1135PubMedCrossRefGoogle Scholar
  110. 110.
    Kono T, Tomita I, Chisato N et al (2004) Successful low-dose chemotherapy using vinblastine and methotrexate for the treatment of an ileoanal pouch mesenteric desmoid tumor: report of a case. Dis Colon Rectum 47:246–249PubMedCrossRefGoogle Scholar
  111. 111.
    Gega M, Yanagi H, Yoshikawa R et al (2006) Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 24(1):102–105PubMedCrossRefGoogle Scholar
  112. 112.
    Patel SR, Benjamin RS (2006) Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol 24:1–2CrossRefGoogle Scholar
  113. 113.
    Hartley JE, Church JM, Gupta S et al (2004) Significance of incidental desmoids identified during surgery for familial adenomatous polyposis. Dis Colon Rectum 47:334–340PubMedCrossRefGoogle Scholar
  114. 114.
    Cohen Z, Berg T (1998) Invited editorial. Dis Colon Rectum 41:1355–1356CrossRefGoogle Scholar
  115. 115.
    Tonelli F, Batignani G, Ficari F et al (1997) Straight ileo-anal anastomosis with multiple ileal myotomies as an alternative to pelvic pouch. Int J Colorectal Dis 12:261–266PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Francesco Tonelli
    • 1
  • Lucia Picariello
    • 2
  • Gabriella Nesi
    • 3
  • Alessandro Franchi
    • 3
  • Rosa Valanzano
    • 1
  • Corrado R. Asteria
    • 1
  • Maria Luisa Brandi
    • 2
  1. 1.Department of Clinical PhysiopathologyUniversity of FlorenceFlorenceItaly
  2. 2.Department of Internal MedicineUniversity of FlorenceFlorenceItaly
  3. 3.Department of Human Pathology and OncologyUniversity of FlorenceFlorenceItaly

Personalised recommendations